NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis $15.60 +0.53 (+3.52%) As of 11/9/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendFinancialsInsider TradesOptions ChainSEC Filings About Aerovate Therapeutics Stock (NASDAQ:AVTE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aerovate Therapeutics alerts:Sign Up Key Stats Today's Range$14.78▼$16.1450-Day Range$13.41▼$21.4052-Week Range$89.95▼$99.05Volume739,449 shsAverage Volume53,591 shsMarket Capitalization$452.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary arterial hypertension (PAH), a progressive disorder involving elevated blood pressure in the arteries of the lungs. The company was headquartered in Cambridge, Massachusetts, and its research programs were aimed at addressing the underlying vascular changes associated with pulmonary diseases. Aerovate’s lead product candidate was AV-101, an inhaled dry-powder formulation of imatinib, a tyrosine kinase inhibitor. The company developed AV-101 for direct delivery to the lungs, with the goal of improving pulmonary vascular function while limiting systemic exposure. The product candidate was evaluated in the IMPAHCT clinical program for patients with PAH. In 2024, Aerovate reported that the IMPAHCT study did not meet its primary endpoint and discontinued further development of AV-101. The company subsequently announced plans to explore strategic alternatives and reduce operations. As a result, Aerovate’s activities have been substantially curtailed compared with its earlier focus as a clinical-stage drug developer. Information about ongoing operations and current leadership may be limited.AI Generated. May Contain Errors. Read More Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTE Stock News HeadlinesAerovate Therapeutics (NASDAQ:AVTE) Stock Jumps 3.2% - Still a Buy?November 6, 2026 | americanbankingnews.comJade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 MillionApril 28, 2025 | globenewswire.comWhy Iran May Only Be the First MoveTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.November 10 at 1:00 AM | Behind the Markets (Ad)Aerovate Stockholders Approve Merger Proposal With Jade BiosciencesApril 23, 2025 | nasdaq.comAerovate Therapeutics stockholders approve proposed merger with Jade BiosciencesApril 23, 2025 | markets.businessinsider.comAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related ProposalsApril 21, 2025 | prnewswire.comAerovate Therapeutics declares special cash dividend, estimated $2.40 per shareApril 10, 2025 | markets.businessinsider.comAerovate Therapeutics sees $67.6M-$69.6M dividend in connection with JadeApril 9, 2025 | markets.businessinsider.comSee More Headlines AVTE Stock Analysis - Frequently Asked Questions How have AVTE shares performed this year? Aerovate Therapeutics' stock was trading at $15.43 at the beginning of 2026. Since then, AVTE stock has decreased by 2.3% and is now trading at $15.07. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) issued its quarterly earnings data on Friday, April, 25th. The company reported ($3.15) earnings per share for the quarter, beating the consensus estimate of ($10.50) by $7.35. When did Aerovate Therapeutics' stock split? Shares of Aerovate Therapeutics reverse split on the morning of Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $122 million in an IPO on Tuesday, June 29th 2021. The company issued 8,682,142 shares at $13.00-$15.00 per share. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVTE CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees20Year Founded2018Profitability EPS (Trailing Twelve Months)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-90.19% Return on Assets-77.47% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio8.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book3.94Miscellaneous Outstanding Shares28,985,000Free Float21,685,000Market Cap$452.17 million OptionableOptionable Beta0.95 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AVTE) was last updated on 11/9/2026 by MarketBeat.com Staff. From Our PartnersInside Nevada's 60 Million Ounce Gold CorridorBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole unt...USA Capital Gold | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredOfficial Black Friday Sale Is Live (Trading Indicator)Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
